Xinxia Liu

Dr. Xinxia Liu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2024 in Integrative Medicine Research
Verified
Journal Article
Open access
SHShanshan Huang
Shanshan Huang
YWYuting Wang
Yuting Wang
YWYifan Wu
Yifan Wu
PHPuchen Huang
Puchen Huang
YDYu Dong
Yu Dong
XLXinxia Liu
Xinxia Liu
Assess the safety and effectiveness of acupuncture for acute ischemic stroke (AIS). We conducted a comprehensive search across the PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), Wanfang, and SinoMed databases from their inception until October 3, 2023. Two reviewers screened eligible randomized controlled trials (RCTs) according to criteria and extracted data using a pre-established form. Cochrane tool was used for risk of bias assessment, and Revman 5.3 was used for subsequent meta-analysis. The GRADE tool will be used to assess the quality of evidence. Thirty-one RCTs were included, involving 3604 patients. Meta-analysis showed that compared with conventional treatments (CTs), acupuncture combined with CTs could improve in National Institutes of Health Stroke Scale (NIHSS) and Efficiency (MD:1.70, 95 %CI [-2.27, -1.14], P < 0.00001;RR: 1.21, 95 %CI [1.12, 1.31], P < 0.00001,);On the Chinese Stroke Scale (CSS) and effectiveness based on CSS, acupuncture showed positive effects (MD:4.33, 95 %CI [-5.67, -2.98], P < 0.00001; RR: 1.26, 95 %CI [1.13, 1.41], P < 0.0001). Furthermore, ADL, Fugl-Meyer Assessment Scale (FMA), prognosis analyses also showed the effectiveness of acupuncture. (SMD: 0.98, 95 % CI [0.64, 1.31], P < 0.00001; MD: 16.46, 95 %CI [12.56, 20.35], P < 0.00001; RR: 0.38, 95 %CI [0.16, 0.89], P = 0.03). However, the certainty of evidence was low. According to current evidence, Acupuncture may be effective and safe for AIS. The future still needs high-quality evidence to support this conclusion.

28 February 2025 in ALPHA PSYCHIATRY
Verified
Journal Article
Open access
PDF file
JZJIE ZHANG
JIE ZHANG
YZYing Zhang
Ying Zhang
JPJunjiao Ping
Junjiao Ping
JLJiali Luo
Jiali Luo
HHHaifeng Huang
Haifeng Huang
XLXinxia Liu
Xinxia Liu
Objective: Cognitive impairment and depression significantly reduce quality of life in the aging population. This study aimed to investigate the prevalence of depressive symptoms and cognitive impairment and explore its relationship in the elderly. Methods: A total of 1645 elderly people in nursing homes and 4703 elderly people in the community were enrolled in the survey. The Patient Health Questionnaire-9 and Ascertain Dementia-8 were employed to evaluate depressive symptoms and cognitive impairment. Results: The overall prevalence of cognitive impairment was 12.5% in the community-dwelling group and 52.2% in the nursing home group. The prevalence of cognitive impairment in nursing homes was significantly higher than that in community-dwelling groups for the same age group (p < 0.001). The overall prevalence of depressive symptoms was 3.9% in the community-dwelling group and 2.0% in the nursing home group. The prevalence of depressive symptoms increased with age in the community-dwelling group (p < 0.001). The binary logistic regression results showed that the type of care mode affected the prevalence of cognitive impairment, and the elderly in nursing homes had a high risk of cognitive impairment (odds ratio [OR] = 3.528, 95% confidence interval [CI]: 2.209–5.635, p < 0.001); depressive symptoms had a significant positive correlation with the odds of cognitive impairment (OR = 1.854, 95% CI: 1.052–3.266, p < 0.05); and the cognitive impairment rate increased with age (OR = 1.412, 95% CI: 1.044–1.910, p < 0.05). Conclusions: There was an increased prevalence in cognitive impairment as well as depressive symptoms in the aging population in Zhongshan city. Population-based mental health strategies need to be urgently implemented for the aging.

16 December 2021 in Genes and Environment
Verified
Journal Article
Open access
PDF file
YLYao Lu
Yao Lu
XLXinxia Liu
Xinxia Liu
ZZZhiqiang Zhao
Zhiqiang Zhao
XOXiaoyan Ou
Xiaoyan Ou
YYYarui Yang
Yarui Yang
YHYun He
Yun He
Background: Workers in electronics manufacturers may be exposed to various occupational hazards such as isopropanol, lead, and noise. Telomeres are special segments of cap-like DNA protein complex at end of liner chromosomes in eukaryotic cells. Telomere length is a potential marker of genetic damage. The aim of this study is to evaluate the effect of occupational hazards on the relative telomere length (rTL) of peripheral blood cells of workers in an electronics manufacturer, and to explore whether relative telomere length could be a biomarker for assessing genetic damage in the electronics manufacturing industry. Methods: We investigated a large-scale electronics manufacturer in the Pearl River Delta Region. We ultimately collected 699 qualified workers (248 with isopropanol exposure, 182 with lead exposure, 157 with noise exposure, and 112 controls). During physical examination of the workers, we gave them questionnaires to understand their health statuses and living habits. We also collected peripheral blood samples from these workers to test exposure levels and rTL in the leucocytes. Results: The concentrations of air isopropanol in all monitored workshops was 25.3 mg/m3 and air lead smoke was 0.020 mg/m3. The maximum equivalent continuous A sound level noise exposure position was 82.2dB (A). All were lower than those in the Occupational Exposure Limits in Workplaces in China. Urinary acetone in the isopropanol exposed group was 1.04 (0, 1.50) mg/L, and cumulative urinary acetone was 1.48 (0, 5.09) mg-years/L. Blood lead levels (BLLs) were 28.57 (22.77, 37.06) µg/dL, and cumulative blood lead levels (CBLLs) were 92.75 (55.47, 165.13) µg-years/dL. rTL was different between occupational exposed workers and controls: rTL was 0.140 units (95 % CI: 0.022, 0.259) shorter in lead exposed workers and 0.467 units (95 % CI: 0.276–0.658) shorter in noise exposed workers compared to the controls. There is no statistical difference in rTL between isopropanol exposure workers and the controls. In order to elucidate the relationship between rTL and occupational hazards exposure, we divided the isopropanol exposure workers into three groups (0, ~1.43 mg/L, and >1.43 mg/L). None of the rTL difference was statistically significant among exposed workers at different uroacetone levels (P>0.05). The groups with ≥100 µg/dL blood lead had shorter rTL than the group with blood lead below 100 µg/dL (F=4.422, P=0.013). We incorporated age, gender, birthplace, race, education level, smoking, and alcohol consumption into the linear regression equation. Only blood lead concentration (X) was entered into the regression equation, yielding a multivariate linear regression equation of Y=0.397-0.124X (F=8.091, P=0.005). Workers with different hearing loss also had statistically significant differences in rTL (F=5.731, P=0.004). rTL was a protective factor for the occurrence of noise-induced hearing loss (NIHL). The longer the rTL, the lower the risk of NIHL [OR=0.64 (0.42, 0.98)]. Conclusions: rTL was shorter in lead exposed workers and noise exposed workers, and it was a protective factor for the occurrence of the noise-induced hearing loss. Thus, rTL of peripheral blood may be a sensitive marker of genetic damage among workers in environments with lead and noise exposure.

13 February 2025 in Experimental Gerontology
Verified
Journal Article
Open access
YZYing Zhang
Ying Zhang
JPJunjiao Ping
Junjiao Ping
DCDong Cui
Dong Cui
ZTZhenkun Tan
Zhenkun Tan
JLJiali Luo
Jiali Luo
XLXinxia Liu
Xinxia Liu
Late-life depression is a prevalent public health issue among the elderly. Imbalances in trace elements are increasingly recognized as associated with depression; however, the majority of current research has concentrated on examining the link between blood-based trace elements levels and depressive symptoms. Our objective was to determine if a similar correlation is observed between urinary trace elements levels and depressive symptoms. We employed stratified, multi-stage random sampling to recruit 400 participants, aged 60 years or older, from a community-based population in a city located in southern China. The Patient Health Questionnaire-9 Items (PHQ-9) was utilized to evaluate depressive symptoms. The concentration of trace elements in urine was detected by inductively coupled plasma mass spectrometry. Multiple logistic regression analysis was conducted to assess the association between urinary trace elements levels and depressive symptoms, as well as the interactions between these levels and potential covariates. The Restricted Cubic Spline (RCS) model with four knots to further explore the association between urinary trace elements and depressive symptoms risk after adjusting for the confounders. A total of 391 participants were investigated, including 50 (12.6 %) in depressive symptom group and 341 (87.4 %) in non-depressive symptom group. Urinary copper levels were positively correlated with depressive symptoms. Compared with the lowest tertile of urinary copper, the multivariate adjusted odds ratios of depressive symptom were 2.58 (1.18-5.64) in tertile 3. Furthermore, we found the interactions between urinary copper and gender were p < 0.05. The multivariate correction OR for T3 versus T1 in males was 21.10 (1.79-248.13) (Pfor trend = 0.002). RCS analysis revealed a positive association between copper levels and depressive symptoms (P-overall association = 0.025, and P-nonlinear = 0.161). No significant difference was observed in the risk of developing depressive symptoms among individuals with urinary copper concentrations below 8.22 μg/g creatinine. However, the risk of depressive symptoms increases progressively as the urinary copper concentration exceeds this threshold. Urinary copper levels are correlated with the development of depressive symptoms, and copper exposure in men is more sensitive to depressive symptoms. Urinary copper, as a non-invasive test, is a promising indicator of depression symptoms in environmental exposure.

29 October 2024 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
YZYing Zhang
Ying Zhang
JWJun Wang
Jun Wang
HZHaibo Zhang
Haibo Zhang
ZTZhenkun Tan
Zhenkun Tan
YZYingyan Zheng
Yingyan Zheng
\Z\R\Nying Zhang
\R\Nying Zhang
Objective: Cerebrospinal fluid biomarkers are challenging to use for diagnosing mild cognitive impairment (MCI) in large populations, and there is an urgent need for new blood biomarkers. The aim of this study is to investigate whether astrocyte activation is correlated with hippocampal atrophy, and to assess the potential of glial fibrillary acidic protein (GFAP) as a biomarker for diagnosing MCI among community-dwelling older individuals.Methods: This cross-sectional study included 107 older adults. The levels of GFAP in serum were measured, and the volumetric assessment of gray matter within hippocampal subregions was conducted using Voxel-Based Morphometry (VBM). The relationship between hippocampal subregion volume and blood biomarkers were analyzed using partial correlation. The effectiveness of blood biomarkers in differentiating MCI was assessed using a receiver operating characteristic (ROC) curve.Results: We found that serum GFAP levels were significantly elevated in the MCI group compared to the cognitively normal (CN) group. Additionally, individuals with MCI exhibited a reduction gray matter volume in specific hippocampal subregions. Notably, the right dentate gyrus (DG) and right cornu ammonis (CA) subregions were found to be effective for distinguishing MCI patients from CN individuals. Serum levels of GFAP demonstrate a sensitivity of 65.9% and a specificity of 75.6% in differentiating patients with MCI from CN individuals.Conclusion: Specific atrophy within hippocampal subregions has been observed in the brains of community-dwelling elderly individuals. Elevated levels of circulating GFAP may serve as a sensitive peripheral biomarker indicative of hippocampal-specific cognitive alterations in patients with MCI.

11 July 2025 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
GYGaolei Yao
Gaolei Yao
YHYuan Huang
Yuan Huang
JPJunjiao Ping
Junjiao Ping
YHYixuan Han
Yixuan Han
LLLiming Lu
Liming Lu
HLHuipeng Lu
Huipeng Lu
Introduction: To objectively and accurately evaluate the clinical efficacy of transcranial direct current stimulation (tDCS) for schizophrenia, we conducted this systematic review and exploratory meta-analysis (PROSPERO: CRD420251002632).Methods: Firstly, randomized controlled trials (RCTs) related to the adjunctive use of tDCS for schizophrenia were searched on PubMed, Embase and Web of Science databases according to search strategies developed in advance. Secondly, the eligible articles were screened according to the inclusion and exclusion criteria. Finally, the data were extracted and a complete meta-analysis was performed. Meanwhile, we also completed publication bias analysis and sensitivity analysis. Statistical analysis was conducted using RevMan software (version 5.4).Results: We ultimately included 11 eligible RCTs. The results of the exploratory meta-analysis indicated that the adjunctive use of tDCS seems to be able to enhance the cognitive function of patients (the Paced Auditory Serial Addition Task: standardized mean deviation (SMD) = 3.57, 95% confidence interval (CI) (2.60, 4.54), P < 0.00001). Subgroup analyses showed that the adjunctive use of tDCS at 15 sessions (Clinical Global Impression-Schizophrenia scale: SMD= -0.56, 95% CI (-0.87, -0.25), P=0.0004) or twice daily (Clinical Global Impression-Schizophrenia scale: SMD= -0.85, 95% CI (-1.67, -0.03), P=0.04) also decreased the disease severity.Discussion: This exploratory meta-analysis revealed that tDCS in the treatment of schizophrenia appears capable of improving cognitive function and effectively reducing the severity of the disease. What’s more, tDCS has great development potential in schizophrenia, and it may be written into the guidelines for non-drug treatment of schizophrenia in the future. As a matter of fact, this exploratory study points out the direction for future scientific research and clinical practice.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251002632.